Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Buy

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Y-mAbs Therapeutics, Inc. Common Stock (YMAB)

Pharmaceutical Preparations

https://www.ymabs.com

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.

230 PARK AVENUE, SUITE 3350
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/21/2018

Market Cap

550,659,879

Shares Outstanding

43,620,000

Weighted SO

43,621,618

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

TCRR --.--%

RVMD --.--%

BDTX --.--%

BCEL --.--%

PASG --.--%

BLUE --.--%

MRSN --.--%

ZNTL --.--%

TVTX --.--%

Beta

0.6530

Last Div

0.0000

Range

4.69-20.9

Chg

0.1450

Avg Vol

288132

Mkt Cap

550659879

Exch

NASDAQ

Country

US

Phone

646 885 8505

DCF Diff

17.8277

DCF

-0.0877

Div Yield

0.0000

P/S

6.3626

EV Multiple

-17.4491

P/FV

5.7050

Div Yield %

0.0000

P/E

-22.0979

PEG

-0.4774

Payout

0.0000

Current Ratio

2.9161

Quick Ratio

2.7206

Cash Ratio

1.7899

DSO

161.1726

DIO

315.0604

Op Cycle

476.2330

DPO

377.7908

CCC

98.4422

Gross Margin

0.8862

Op Margin

-0.3194

Pretax Margin

-0.2770

Net Margin

-0.2844

Eff Tax Rate

-0.0268

ROA

-0.1709

ROE

-0.2488

ROCE

-0.2749

NI/EBT

1.0268

EBT/EBIT

0.8671

EBIT/Rev

-0.3194

Debt Ratio

0.0088

D/E

0.0134

LT Debt/Cap

0.0045

Total Debt/Cap

0.0132

Int Coverage

-21.3805

CF/Debt

-9.8532

Equity Multi

1.5108

Rec Turnover

2.2647

Pay Turnover

0.9661

Inv Turnover

1.1585

FA Turnover

63.7305

Asset Turnover

0.6009

OCF/Share

-0.2852

FCF/Share

-0.2852

Cash/Share

1.7674

OCF/Sales

-0.1450

FCF/OCF

1.0000

CF Coverage

-9.8532

ST Coverage

-14.9086

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

5.7050

P/B

5.7050

P/S

6.3626

P/E

-22.0979

P/FCF

-43.8668

P/OCF

-43.3280

P/CF

-43.3280

PEG

-0.4774

P/S

6.3626

EV Multiple

-17.4491

P/FV

5.7050

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation